OJSC Pharmstandard-Leksredstva, Pharmstandard’s structure based in Kursk, plans to draw 500 million rubles in 2019 for modernization.
The company plans to start manufacturing 15 new pharmaceutical products in 2019 and to increase output volumes by 5%, according to the Kursk regional administration.
The company currently produces 417 drugs, including 54 entered on the list of vital and essential medications. It employs about 2,000 personnel and puts out 600 million packages, annually.
In September 2018, Pharmstandard-Leksredstva commissioned a new facility in Kursk worth over 1.9 billion rubles for making import-substituting drugs for treating asthma. Its annual design capacity is 5.4 million packages.
Pharmstandard-Leksredstva is the largest manufacturer of finished drugs in Russia’s Central Black Soil Region. It ranks among the country’s top five drugmakers. It was integrated into Pharmstandard Group in 2003.
Pharmstandard is one of Russia’s biggest pharmaceutical companies. Its controlling stake is held by Augment Investments Ltd. (Cyprus), whose beneficiary is Viktor Kharitonin. The group is comprised of JSC Pharmstandard (the head company), OJSC Pharmstandard-Leksredstva, OJSC Pharmstandard-UfaVITA (Ufa), OJSC Pharmstandard-Tomskhimpharm (Tomsk), CJSC Lekko and JSC Biomed named after Mechnikov (both based in Moscow), and the seller, LLC